KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Non-Current Debt (2017 - 2026)

Amneal Pharmaceuticals has reported Non-Current Debt over the past 9 years, most recently at $2.6 billion for Q4 2025.

  • For Q4 2025, Non-Current Debt rose 18.66% year-over-year to $2.6 billion; the TTM value through Dec 2025 reached $2.6 billion, up 18.66%, while the annual FY2025 figure was $2.6 billion, 18.66% up from the prior year.
  • Non-Current Debt for Q4 2025 was $2.6 billion at Amneal Pharmaceuticals, roughly flat from $2.6 billion in the prior quarter.
  • Over five years, Non-Current Debt peaked at $2.7 billion in Q2 2021 and troughed at $36.8 million in Q1 2021.
  • A 5-year average of $2.3 billion and a median of $2.6 billion in 2023 define the central range for Non-Current Debt.
  • On a YoY basis, Non-Current Debt climbed as much as 7527.71% in 2021 and fell as far as 98.67% in 2021.
  • Year by year, Non-Current Debt stood at $2.7 billion in 2021, then fell by 3.29% to $2.6 billion in 2022, then fell by 7.95% to $2.4 billion in 2023, then dropped by 9.4% to $2.2 billion in 2024, then grew by 18.66% to $2.6 billion in 2025.
  • Business Quant data shows Non-Current Debt for AMRX at $2.6 billion in Q4 2025, $2.6 billion in Q3 2025, and $2.1 billion in Q2 2025.